Citation:Tada H, Tanaka M, Katakami N, Kurata T, Mitsudomi T, Negoro S, Kudoh S, Nishiyama H, Nishimura Y, and Nakagawa K 2009

Citation

Tada H, Tanaka M, Katakami N, Kurata T, Mitsudomi T, Negoro S, Kudoh S, Nishiyama H, Nishimura Y, and Nakagawa K. Phase III study of induction chemotherapy (docetaxel and carboplatin) with or without radiotherapy followed by surgery in patients with stage IIIA (pN2) non-small cell lung cancer (NSCLC):WJTOG9903. Journal of Clinical Oncology 2009;27:15 SUPPL. 1 (7556) Available from: http://www.embase.com.ezproxy1.library.usyd.edu.au/search/results?subaction=viewrecord&rid=2&page=1&L70242257.

Critical appraisals

• Assign a critical appraisal

Cited by

1. What is the clinical benefit of the addition of neoadjuvant radiotherapy to neoadjuvant chemotherapy in stage IIIA (N2) NSCLC?